J.W. Cole Advisors’s Matinas BioPharma MTNB Stock Holding History

J.W. Cole Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-215	Closed	-$1.7K	–	955
2024 Q2	$1.7K	Hold	215	–	–	﹤0.01%	889
2024 Q1	$2.91K	Hold	215	–	–	﹤0.01%	880
2023 Q4	$2.33K	Hold	215	–	–	﹤0.01%	815
2023 Q3	$1.4K	Hold	215	–	–	﹤0.01%	734
2023 Q2	$3.87K	Hold	215	–	–	﹤0.01%	757
2023 Q1	$5.05K	Hold	215	–	–	﹤0.01%	774
2022 Q4	$5.38K	Hold	215	–	–	﹤0.01%	741
2022 Q3	$7K	Hold	215	–	–	﹤0.01%	725
2022 Q2	$8K	Hold	215	–	–	﹤0.01%	733
2022 Q1	$9K	Hold	215	–	–	﹤0.01%	805
2021 Q4	$11K	Hold	215	–	–	﹤0.01%	832
2021 Q3	$14K	Hold	215	–	–	﹤0.01%	476
2021 Q2	$8K	Hold	215	–	–	﹤0.01%	736
2021 Q1	$11K	Buy	+215	New	+$14.4K	﹤0.01%	668

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

J.W. Cole Advisors's MTNB Position: Q3 2024 in Review

J.W. Cole Advisors sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 215 shares — an estimated $1.7K sold.

J.W. Cole Advisors first reported a position in MTNB in Q1 2021 and held it in 14 quarters. The position peaked at $14K in Q3 2021. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

J.W. Cole Advisors reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
J.W. Cole Advisors sold 215 Matinas BioPharma shares in Q3 2024, an estimated $1.7K.
J.W. Cole Advisors first reported a position in Matinas BioPharma in Q1 2021 and held it in 14 quarters.
J.W. Cole Advisors's Matinas BioPharma position peaked at $14K in Q3 2021.
18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on J.W. Cole Advisors's 13F filing for Q3 2024, filed 24 Oct 2024.